CWP-232291

N/A

Report date: 2025/12/27 21:27:51
NME

Base Information

Drug NameCWP-232291
Drug Alias NameCWP-291CWP-232291
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCatenin beta 1 inhibitorsWnt signalling pathway inhibitors
TargetsCatenin beta 1
Therapy Area/IndicationsPrimary MyelofibrosisMyelodysplastic SyndromesMultiple Myeloma +[5
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesJw Pharmaceutical Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJw Pharmaceutical Corp
Active IndicationsN/A
Inactive IndicationsPrimary MyelofibrosisMyelodysplastic SyndromesMultiple Myeloma +[5

Other Information

ATC CodeN/A
Related LinksN/A